VentriPoint Diagnostics Valuation
| VPT Stock | CAD 0.14 0.01 6.67% |
VentriPoint Diagnostics seems to be overvalued based on Macroaxis valuation methodology. Our model measures the value of VentriPoint Diagnostics from inspecting the company fundamentals such as Return On Equity of -29.73, shares owned by insiders of 2.03 %, and Current Valuation of 25.85 M as well as reviewing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting VentriPoint Diagnostics' valuation include:
Price Book 7.1297 | Enterprise Value | Enterprise Value Ebitda (6.68) | Price Sales 144.5715 | Enterprise Value Revenue 155.2347 |
Overvalued
Today
Please note that VentriPoint Diagnostics' price fluctuation is out of control at this time. Calculation of the real value of VentriPoint Diagnostics is based on 3 months time horizon. Increasing VentriPoint Diagnostics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the VentriPoint stock is determined by what a typical buyer is willing to pay for full or partial control of VentriPoint Diagnostics. Since VentriPoint Diagnostics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of VentriPoint Stock. However, VentriPoint Diagnostics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.14 | Real 0.12 | Hype 0.14 | Naive 0.15 |
The intrinsic value of VentriPoint Diagnostics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence VentriPoint Diagnostics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of VentriPoint Diagnostics helps investors to forecast how VentriPoint stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of VentriPoint Diagnostics more accurately as focusing exclusively on VentriPoint Diagnostics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use VentriPoint Diagnostics' intrinsic value based on its ongoing forecasts of VentriPoint Diagnostics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against VentriPoint Diagnostics' closest peers.
VentriPoint Diagnostics Cash |
|
VentriPoint Valuation Drivers Correlation
Many accounts on the financial statements of VentriPoint Diagnostics are highly interrelated and sometimes correlated. Consequently, when conducting VentriPoint's valuation analysis, one should examine all of the accounts reported to obtain a complete picture of its financial situation. We provide a unique feature to present a conventional correlation table purposely composed against different valuation-related drivers of VentriPoint
Click cells to compare fundamentals
VentriPoint Valuation Trend
Analysing the historical paterns of VentriPoint Diagnostics' enterprise value and its market capitalization is a good way to estimate and gauge the value of VentriPoint Diagnostics over time and is usually enough for investors to make rational market timing decisions.
VentriPoint Diagnostics Total Value Analysis
VentriPoint Diagnostics is at this time estimated to have takeover price of 25.85 M with market capitalization of 24.07 M, debt of 1.36 M, and cash on hands of 713.21 K. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the VentriPoint Diagnostics fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
25.85 M | 24.07 M | 1.36 M | 713.21 K |
VentriPoint Diagnostics Investor Information
The company recorded a loss per share of 0.03. VentriPoint Diagnostics had not issued any dividends in recent years. The entity had 1:10 split on the 7th of December 2015. Based on the key indicators related to VentriPoint Diagnostics' liquidity, profitability, solvency, and operating efficiency, VentriPoint Diagnostics may be sliding down financialy. It has an above-average probability of going through some form of financial hardship next quarter.VentriPoint Diagnostics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. VentriPoint Diagnostics has an asset utilization ratio of 14.46 percent. This indicates that the Company is making C$0.14 for each dollar of assets. An increasing asset utilization means that VentriPoint Diagnostics is more efficient with each dollar of assets it utilizes for everyday operations.VentriPoint Diagnostics Ownership Allocation
VentriPoint Diagnostics shows a total of 166 Million outstanding shares. About 97.97 % of VentriPoint Diagnostics outstanding shares are held by general public with 2.03 (%) owned by insiders and only 0.0 % by institutional holders. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.VentriPoint Diagnostics Profitability Analysis
The company reported the revenue of 95.17 K. Net Loss for the year was (4.92 M) with profit before overhead, payroll, taxes, and interest of 166.49 K.About VentriPoint Diagnostics Valuation
Our relative valuation model uses a comparative analysis of VentriPoint Diagnostics. We calculate exposure to VentriPoint Diagnostics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of VentriPoint Diagnostics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 95.2 K | 99.9 K | |
| Pretax Profit Margin | (52.57) | (55.20) | |
| Operating Profit Margin | (50.45) | (52.98) | |
| Net Loss | (51.69) | (54.28) | |
| Gross Profit Margin | 0.78 | 0.82 |
Additional Tools for VentriPoint Stock Analysis
When running VentriPoint Diagnostics' price analysis, check to measure VentriPoint Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy VentriPoint Diagnostics is operating at the current time. Most of VentriPoint Diagnostics' value examination focuses on studying past and present price action to predict the probability of VentriPoint Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move VentriPoint Diagnostics' price. Additionally, you may evaluate how the addition of VentriPoint Diagnostics to your portfolios can decrease your overall portfolio volatility.